About Cipla Limited

Founded in 1935, Cipla Limited is a global pharmaceutical company focused on making high‑quality medicines accessible across markets, guided by its purpose of “Caring for Life.” It is the third‑largest pharmaceutical company in India, ranks second in South Africa’s prescription market, is the second‑largest Indian exporter to emerging markets and seventh‑largest to Europe, and is fourth by prescriptions for generic inhalation products in the US. Its network spans 46 manufacturing sites producing 50+ dosage forms and 1,500+ products for 74 markets. Key therapeutic strengths include respiratory, anti‑retroviral, urology, cardiology, anti‑infectives and CNS. Cipla is widely recognised for enabling triple anti‑retroviral therapy for HIV/AIDS at under a dollar a day in Africa in 2001, a milestone often cited for advancing access and affordability in global health.

In India, Cipla leads respiratory therapy by market share and continues to build an innovation pipeline in complex generics and inhalation devices. Notable prescription brands include Foracort, the Dytor cardiac franchise and Urimax in urology; in consumer health, anchor brands include Nicotex, Omnigel and Cipladine.

Cipla Limited’s Business Segments

Cipla reports five operating pillars:

• One‑India (Branded prescription, Trade Generics and Consumer Health)
• North America
• One Africa (South Africa, Sub‑Saharan Africa, North Africa and Cipla Global Access)
• Emerging Markets & Europe (EMEU)
• Active Pharmaceutical Ingredients (API)

Cipla Limited’s Revenue by Geography (FY 2024–25, standalone sale of products)

• India (Branded & Trade Generics): Rs 9,249.22 crore; India Others: Rs 134.89 crore
• North America (USA): Rs 2,270.76 crore
• One‑Africa (South Africa, Sub‑Saharan Africa and North Africa): Rs 1,242.12 crore
• Emerging Markets: Rs 1,574.24 crore
• Europe: Rs 1,174.52 crore
• API and others: Rs 465.70 crore

Cipla Limited’s Revenue by Industry Vertical

• One‑India crossed Rs 11,000 crore revenue, driven by branded Rx, trade generics and Cipla Health Limited (CHL).
• North America achieved an all‑time high, led by differentiated and respiratory portfolios.
• EMEU delivered growth of 15% year‑on‑year.
• One Africa posted Rs 3,827 crore, up 14% in rupee terms (ex‑QCIL divestment).
• API business revenue was USD 67 million; therapy mix included oncology, CNS, respiratory, gastrointestinal and cardiovascular.
• For context, Cipla segment revenue contributions: One‑India 42%, North America 29%, One Africa 14%, EMEU 12% and API 2%.

Cipla Limited Key Management

• Umang Vohra, Managing Director and Global Chief Executive Officer
• Dr Y K Hamied, Chairman: provides strategic oversight as non‑executive Chairman.
• Ashish Adukia, Global Chief Financial Officer

Latest Updates on Cipla Limited

• North America momentum: all‑time high USD 934 million revenue; FDA approvals for Lanreotide Injection (ANDA), Nilotinib Capsules (NDA) and Nano‑Paclitaxel (ANDA); filings for inhaled assets including a generic Symbicort and another inhaled product.
• India portfolio and brand scale: Foracort crossed H 900 crore; 26 India brands exceeded H 100 crore; consumer portfolio strengthened with the acquisition of Ivia Beaute brands (Astaberry, Ikin, Bhimsaini).
• Partnerships and in‑licensing: deals with Sanofi (CNS), MannKind (inhaled insulin), Orchid Pharma (AMR portfolio) and Formosa Pharmaceuticals (ophthalmic clobetasol) to deepen chronic and specialty therapies.
• EMEU and Africa: EMEU reached USD 394 million (+15% YoY); One Africa revenue was H 3,827 crore with South Africa private market outperformance and tender strength.
• Manufacturing and quality: multiple site inspections (Patalganga, Kurkumbh, Goa, Virgonagar, Medispray) culminated in USFDA VAI classification and EU GMP compliance certificates.
• Sustainability and operations: India‑based manufacturing sites certified “Zero Waste to Landfill”; advanced wastewater treatment and zero liquid discharge are implemented across sites.
• Recognitions: listed in the Dow Jones Sustainability Indices World and Emerging Markets 2024; ICAI Gold Shield for Financial Reporting; multiple awards for digital engagement, data architecture and safety.